{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-063959","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.702109+00:00","generated_at":"2026-05-22T13:17:25.775849+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TScan Q1 net loss $34.1M; cash runway into Q1 2027; registrational trial H2 2025","bullets":["Revenue $2.2M (up from $0.6M YoY); R&D expense $29.8M; net loss $34.1M vs $30.1M YoY.","Cash, equivalents, and marketable securities $251.7M (plus $5.0M restricted) funding operations into Q1 2027.","On track to initiate registrational trial for TSC-101 and file IND for TSC-102-A0301 in H2 2025.","First patient dosing with multiplex TCR-T therapy expected H1 2025; safety/efficacy data by year-end.","Appointed Stephen Camiolo as SVP Market Access; presenting at ASGCT and Bank of America conference."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-063959","json":"https://secwatch.observer/filing/0000950170-25-063959.json","markdown":"https://secwatch.observer/filing/0000950170-25-063959.md","text":"https://secwatch.observer/filing/0000950170-25-063959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000095017025063959/0000950170-25-063959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000095017025063959/tcrx-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T13:17:25.775849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}